Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586508 · ClinicalTrials.gov registry record · Phase 2
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00586508 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 81 participants.
The verdict
NCT00586508, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
Interventions
- DRUG bevacizumab
- DRUG enzastaurin
- DRUG Enzyme-inducing antiepileptic drugs (EIAED)
- DRUG Non-enzyme inducing antiepileptic drugs (NEIAED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586508
The ClinicalTrials.gov registry entry for NCT00586508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT00586508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586508 about?
NCT00586508 is a clinical study titled "Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas". The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
What is the current status of trial NCT00586508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2007-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00586508?
The interventions under investigation include: bevacizumab (DRUG), enzastaurin (DRUG), Enzyme-inducing antiepileptic drugs (EIAED) (DRUG), Non-enzyme inducing antiepileptic drugs (NEIAED) (DRUG).
Who is sponsoring clinical trial NCT00586508?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.